Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602.

Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Abstract Text:

Takashi Onda,Koji Matsumoto,Taro Shibata,Akihiro Sato,Haruhiko Fukuda,Ikuo Konishi,Toshiharu Kamura,Hiroyuki Yoshikawa, ,

On the basis of promising results of neoadjuvant chemotherapy (NAC) in our previous study (JCOG0206), we have been performing a Phase III study of treatment starting with NAC versus standard treatment starting with primary debulking surgery (PDS) for Stage III/IV müllerian carcinomas (ovarian, tubal and peritoneal carcinomas) since November 2006. The purposes are to prove the non-inferiority of the efficacy and to show the decrease in adverse effects resulting from reduced surgical invasiveness of treatment starting with NAC. Three hundred patients with advanced müllerian carcinomas will be randomized during 3 years. NAC arm patients undergo four cycles of NAC with paclitaxel plus carboplatin followed by interval debulking surgery and an additional four cycles of postsurgical chemotherapy. Standard arm patients undergo PDS and eight cycles of postsurgical chemotherapy with or without interval debulking surgery. The primary endpoint is overall survival. The major secondary endpoints are the incidence of adverse events and parameters representing surgical invasiveness.

Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Publishing Authors By Initials

T Onda,K Matsumoto,T Shibata,A Sato,H Fukuda,I Konishi,T Kamura,H Yoshikawa, ,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Japanese journal of clinical oncology

VOLUME: 38

Page Numbers: 74-7

Journal Abbreviation: Jpn. J. Clin. Oncol.

ISSN: 1465-3621

DAY: 8

MONTH: Jan

YEAR: 2008

Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 313225

Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602.

AFFILIATION: Division of Gynecologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. taonda@ncc.go.jp

Country: Japan

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Jpn J Clin Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602 Related Publications

• Bioactive constituents from Chinese natural medicines. XXVI. Chemical structures and hepatoprotective effects of constituents from roots of Rhodiola sachalinensis.
• Biological characters of bats in relation to natural reservoir of emerging viruses.
• Candida soluble cell wall beta-D-glucan induces lung inflammation in mice.
• Characterization of virus-induced gene silencing in tobacco plants infected with apple latent spherical virus.
• Cheravirus and Sadwavirus: two unassigned genera of plant positive-sense single-stranded RNA viruses formerly considered atypical members of the genus Nepovirus (family Comoviridae).
• Contribution Of Oxidative Stress To Protein Catabolism In Skeletal Muscle: 1856: Board #144 May 31 9:00 AM - 10:30 AM.
• Correction of deformity and shortening due to post traumatic epiphyseal arrest by distraction osteogenesis.
• Development of an intermolecular transposition assay system in Bacillus subtilis 168 using IS4Bsu1 from Bacillus subtilis (natto).
• First-line therapy for theophylline-associated seizures.
• Gene expression clusters of a lipopolysaccharide-stimulated pathway in peripheral blood monocytes of Japanese patients with Crohn's disease.
• Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia.
• Increased intestinal luminal carbon monoxide gas in patients with ulcerative colitis.
• Intra-extradural plexiform schwannoma of the cervical spine.
• Involvement of BMP-2 signaling in a cartilage cap in osteochondroma.
• Localization of bone morphogenetic protein-2 in human osteoarthritic cartilage and osteophyte.
• Long-term follow-up of juvenile acute nonproliferative glomerulitis (JANG).
• New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
• Reduction of Visceral Adiposity Underlies the Improvement of Arterial Stiffness through Aerobic Exercise Training: 1529: Board #19 May 30 3:30 PM 5:00 PM.
• Resonance Raman spectra of the FMN of the bovine heart NADH: ubiquinone oxidoreductase, the largest membrane protein in the mitochondrial respiratory system.
• Role of interleukin-6 in fibrinolytic changes induced by lipopolysaccharide in mice.
• Rubiscolin-6, a delta opioid peptide derived from spinach Rubisco, has anxiolytic effect via activating sigma1 and dopamine D1 receptors.
• Surgical outcomes after treatment of fractures in femur and tibia in pycnodysostosis.
• The effects of antipoverty programs on children's cumulative level of poverty-related risk.
• The mode of destruction in shoulders with rheumatoid arthritis based on radiographic findings.
• Thermodynamic quantities of surface formation of aqueous electrolyte solutions VII. Aqueous solution of alkali metal nitrates LiNO3, NaNO3, and KNO3.
• Treatment of temporomandibular pain with the selective serotonin reuptake inhibitor paroxetine.
• Up-regulation of thrombin activity induced by vascular endothelial growth factor in asthmatic airways.
• Working nonstandard schedules and variable shifts in low-income families: associations with parental psychological well-being, family functioning, and child well-being.
• [Randomized controlled clinical trials for IgA nephropathies]
• beta-Lactotensin, a neurotensin agonist peptide derived from bovine beta-lactoglobulin, enhances memory consolidation in mice.